AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH-AD)
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Sponsor: Cerecin
This PHASE2/PHASE3 trial investigates Alzheimer's Disease and is currently completed. Cerecin leads this study, which shows 13 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Sep 2021 — Apr 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 8 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2_PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2019 — Dec 2019 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE2_PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
May 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cerecin
For direct contact, visit the study record on ClinicalTrials.gov .